Intracellular receptors
From Proteopedia
(Difference between revisions)
| Line 48: | Line 48: | ||
RXRα homodimers have also been shown to assemble on DR-2 tandem repeats, sequences with the same organization as DR-1, but with two nucleotides as a spacer. The DNA interaction is similar with DR-2 repeats, just spaced further apart. | RXRα homodimers have also been shown to assemble on DR-2 tandem repeats, sequences with the same organization as DR-1, but with two nucleotides as a spacer. The DNA interaction is similar with DR-2 repeats, just spaced further apart. | ||
* [[PPAR-gamma]] | * [[PPAR-gamma]] | ||
| + | Peroxisome proliferator-activated receptor gamma (<scene name='PPAR-gamma/Ppar_gamma/3'>PPAR</scene>γ) is a protein in the nuclear receptors subfamily. It is one of three isotypes (-α, -β/ δ, and -γ) [1] of [[PPAR]] receptors and has two protein isoforms governed by splice variations, which result in differences in the length of the amino (N)-terminal region (PPARγ1 and PPARγ2) [2]. PPARγ is involved in transcriptional regulation of glucose and lipid homeostasis [1], and helps regulate adipocyte differentiation [3]. It has a <scene name='PPAR-gamma/Binding_pocket/1' target='1'>large binding pocket</scene>, which allows it to interact with a wide array of ligands. <scene name='PPAR-gamma/Interacting_residues/3'>Ligand binding</scene> typically triggers a conformational change of PPARγ, notably in the activation function-2 <scene name='PPAR-gamma/Af-2_domain/2'>(AF-2) domain</scene>, which aids in the recruitment of co-regulatory factors to regulate gene transcription. PPARγ can form a <scene name='PPAR-gamma/Ppar_rxr/3'>heterodimer</scene> with retinoic X receptor alpha (RXRα), a process necessary for most PPARγ-DNA interactions [4]. PPARγ is a molecular target for antidiabetic drugs such as thiazolidinediones (TZDs), which makes the protein a target for Type II Diabetes (T2D) drug research. Due to its involvement in metabolic and inflammatory processes, PPARγ also holds potential for treatments of many metabolic and chronic-inflammatory diseases, such as metabolic syndrome and inflammatory bowel disease, respectively. Errors in PPARγ-related regulation have also been implicated in atherosclerosis and various cancers, like colorectal, breast, and prostate cancers. | ||
* [[Pioglitazone]] is a selective agonist for Peroxisome Proliferator-Activated Receptor Gamma | * [[Pioglitazone]] is a selective agonist for Peroxisome Proliferator-Activated Receptor Gamma | ||
*[[Liver X receptor]] | *[[Liver X receptor]] | ||
Revision as of 12:57, 19 May 2021
| |||||||||||
References
- ↑ Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y
